<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01124565</url>
  </required_header>
  <id_info>
    <org_study_id>RT001-CL025LCL</org_study_id>
    <nct_id>NCT01124565</nct_id>
  </id_info>
  <brief_title>Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults</brief_title>
  <official_title>A Phase 2, Open-Label, Repeat Dose, Multi-Center Study to Evaluate the Safety of RT001 Topical Gel for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revance Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revance Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2)
      sequential applications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Revance is conducting this Phase 2 clinical study to establish the safety of two (2)
      sequential doses of RT001 Topical Gel at Baseline (Day 0) and Week 4 for the treatment of
      moderate to severe LCLs at rest.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of treatment-emergent adverse events based on safety assessments.</measure>
    <time_frame>4 weeks and 8 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Lateral Canthal Lines</condition>
  <condition>Crow's Feet</condition>
  <condition>Facial Wrinkles</condition>
  <arm_group>
    <arm_group_label>RT001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT001 (Botulinum Toxin Type A) Topical Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RT001</intervention_name>
    <description>RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas</description>
    <arm_group_label>RT001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent including authorization to release health information

          -  Female or male, 18 to 65 years of age and in good general health

          -  Willing and able to follow study instructions and likely to complete all study
             requirements

          -  Moderate to severe lateral canthal lines (crow's feet wrinkles)

        Exclusion Criteria:

          -  Any neurological condition that may place the subject at increased risk with exposure
             to Botulinum Toxin Type A, including peripheral motor neuropathic diseases such as
             amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular junctional
             disorders such as Lambert-Eaton syndrome and myasthenia gravis

          -  Muscle weakness or paralysis, particularly in the area receiving study treatment

          -  Active disease or irritation at the treatment areas including the eye and the skin

          -  Pregnant, nursing, or planning a pregnancy during the study; or is a woman of child
             bearing potential (WOCBP) but is not willing to use an effective method of birth
             control

          -  Previous participation in a RT001 clinical study

          -  Previous treatment with botulinum toxin (any serotype)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Schlessinger, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skin Specialists, PC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Total Skin &amp; Beauty Dermatology Center, PC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialists, PC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2010</study_first_submitted>
  <study_first_submitted_qc>May 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2010</study_first_posted>
  <disposition_first_submitted>June 13, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 13, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 27, 2011</disposition_first_posted>
  <last_update_submitted>December 16, 2013</last_update_submitted>
  <last_update_submitted_qc>December 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lateral Canthal Lines</keyword>
  <keyword>Crow's Feet</keyword>
  <keyword>Facial Wrinkles</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

